We proudly present our 2022 impact report, highlighting valuable contributions to advancing science, research, and health equity and the great work we have achieved with our partners.
CTSI Translational Impact: Advancing Equity
Read the report ➡️ https://t.co/6qQiQpIJNH
Our own @DukeBiostats@DukeCancer professor Susan Halabi, PhD, was honored by @uabSOPH this week for career achievement. Notably, she was the 1st statistician ever to be named an @ASCO fellow!
Susan Halabi, PhD, professor of biostatistics and bioinformatics (B&B), received the 21st annual Janet L. Norwood Award for Outstanding Achievement by a Woman in Statistical Sciences from @uabSOPH. Halabi is known for her research on #prostatecancer.
https://t.co/HYGC8NuQ3Z
1 in 8 men will be diagnosed with #prostatecancer in their lifetime. If caught early, most can be cured. Men over 50, talk to your doc ab #prostate#cancer#screening – a simple blood test could save your life. @DukeCancer
Another great addition to the Duke Oncology Pharmacy team! Welcome Andrea who will be working in our GU Medical Oncology Clinic! @Daniel_J_George@DukeCancer
Incredible work by @DukeFellows very best @hannahdzmd with mentorship by @AarmstrongDuke highlighting the importance of the patient voice in prostate cancer trials! 👏🏻👏🏻👏🏻
@DukeGUCancer is hiring a clinical research nurse coordinator. This team is where I got my start in clinical research over 8 years ago and is a great place to learn! @UNCSON @DukeU_NrsngSchl #NurseTwitter https://t.co/J04LM49WgE
Study by esteemed PCCTC investigator @Daniel_J_George (@DukeGUCancer) and colleagues finds black men with chemotherapy-naïve metastatic prostate cancer initiating novel hormonal therapy may have better outcomes than similarly treated white men https://t.co/mrCiWkcV5w
Join us for spring break at Disney! The Duke Urologic Assembly 2022 is on! Both in person and hybrid options are available with a great team of expert speakers for this CME event focused on precision urologic oncology and urology: @DukeGUCancer
https://t.co/4pFMmzTJms
We are back after a break. This time with an episode showcasing resident perspective on managing irAEs. Join hosts @afreenshariffmd@TiansterZhang as they d/w @IMResidencyDuke physicians @nathanhirshy @MFerreiraMD Dr. Harsh Patolia to learn more.
👉 https://t.co/XfGLXUAnlQ
One week to go until #AUA21. Looking forward to debate with @LiMingSu1 on pros and cons of maintaining open RRP experience for urology residency training. Friday September 10th live during plenary session. @DukeUrology @DukeCancer@DukeGUCancer
.@TiansterZhang, of @DukeCancer, discussed key considerations regarding frontline immunotherapy-based combinations in RCC and recent data from pivotal trials examining their use #kcsm https://t.co/1YMYq4g6jX
Today was a bittersweet day as I held my last clinic session @dukemedicine@DukeCancer. 12 yrs here - these are the halls where I gained my clinical acumen, grew into an oncologist, and developed some research skills. I am so sad and so grateful for every minute of these 12 yrs.
Thrilled to share our latest ARCHES analysis by risk/volume/prior therapy to provide valuable information to men with mHSPC. Great teamwork with @AzadOncology@DukeGUCancer@AstellasUS@pfizer https://t.co/FG08uTUVpb$